Mark J. Fitzpatrick

Filings by Mark J. Fitzpatrick span 2 companies, the busiest being Aegerion Pharmaceuticals, Inc. and Chiasma, Inc. Between 23 March 2012 and 4 December 2020, the trades on record add up to 24 filings.

Both buying and selling appear: 4 purchases worth €53k, against 13 sales worth €1.3M. On balance, insiders were net sellers of €1.3M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 7 option exercises.

A typical purchase (the median) is worth €12k.

On 7 December 2020 came the latest disclosure, an option exercise for €21k in Chiasma, Inc. The last insider purchase was made public on 21 December 2018, 2,864 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.